{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Severe (Grade 4) neutropenia was defined as at least 1 ANC value \\<0.5 × 10\\^9/L during the treatment period.","groups":[{"description":"Participants received trilaciclib 200 mg/m\\^2 administered intravenously (IV) once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 1: Cohort 1 Trilaciclib 200 mg/m^2"},{"description":"Participants received trilaciclib 240 mg/m\\^2 administered IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 1: Cohort 2 Trilaciclib 240mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS included all randomized patients who received at least 1 dose of study drug (etoposide, carboplatin, or trilaciclib). Analyses using the FAS were conducted on the basis of the assigned treatment.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)","title":"Occurrence of Severe (Grade 4) Neutropenia in Part 1","type":"SECONDARY","unitOfMeasure":"Participants"}